Key Points
- CTO Raymond Woo sold 11,104 shares on May 1 at an average price of $20.44 for ~$226,966, leaving him with 197,648 shares (a 5.32% ownership reduction valued at about $4.04M).
- This follows a string of recent insider sales — Woo sold 11,112 shares on Apr 1, 8,087 on Mar 2 and 705 on Feb 23, totaling 31,008 shares for roughly $595,000 over the period.
- Company snapshot and analyst view: CeriBell has a $767.7M market cap, reported Q4 EPS of -$0.36 (beating estimates) and revenue of $24.78M, but wide negative margins; analysts have a consensus rating of Moderate Buy with an average target of $23.20.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 11,104 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $20.44, for a total transaction of $226,965.76. Following the completion of the sale, the chief technology officer owned 197,648 shares in the company, valued at $4,039,925.12. This represents a 5.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Raymond Woo also recently made the following trade(s):
- On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72.
- On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The shares were sold at an average price of $18.25, for a total transaction of $147,587.75.
- On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $13,951.95.
CeriBell Stock Performance
Shares of NASDAQ:CBLL opened at $20.27 on Tuesday. The company has a market capitalization of $767.67 million, a price-to-earnings ratio of -13.79 and a beta of 1.00. The firm's 50 day simple moving average is $19.15 and its 200 day simple moving average is $18.55. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. As a group, sell-side analysts forecast that CeriBell, Inc. will post -1.44 earnings per share for the current year.
Hedge Funds Weigh In On CeriBell
Several hedge funds and other institutional investors have recently made changes to their positions in CBLL. Vanguard Group Inc. lifted its holdings in CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company's stock valued at $16,935,000 after purchasing an additional 147,013 shares during the last quarter. Yu Fan lifted its holdings in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company's stock worth $25,345,000 after buying an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company's stock worth $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new stake in shares of CeriBell during the fourth quarter worth $21,930,000. Finally, Novo Holdings A S lifted its holdings in shares of CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company's stock worth $16,857,000 after buying an additional 20,000 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on CBLL. BTIG Research reiterated a "buy" rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CeriBell in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $23.20.
Check Out Our Latest Research Report on CBLL
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
